Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP: stopping strategy vs maintenance JAK inhibitor dose in deep remission ulcerative colitis
2026-525643-32-00Phase 4Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of upadacitinib, tofacitinib and filgotinib in autoimmune colitis (2 arms), sponsored by Assistance Publique–Hôpitaux de Marseille. Primary endpoint: Composite primary endpoint of safety, efficacy, and patient satisfaction at 52 weeks. Planned start Jun 2026; status: authorised.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2026-525643-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525643-32-00.